National and European guidelines recommend a first-line doublet or triplet chemotherapy regimen as induction therapy associated with targeted therapy depending on the KRAS, NRAS and BRAF status for patients with pMMR/MSS non-resectable metastatic colorectal cancer [3]. The gene discussed is BRAF; the disease is metastatic colorectal cancer.